HYPERION THERAP (HPTX) Downgraded by Zacks to UNDERPERFORM

Zacks Zacks Investment Research downgraded shares of HYPERION THERAP (HPTX) from NEUTRAL to UNDERPERFORM on March 07, 2014, with a target price of $27.50.

Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company is developing Ravicti (TM) for urea cycle disorders and hepatic encephalopathy. Hyperion Therapeutics, Inc. is headquartered in South San Francisco, California.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on HYPERION THERAP (HPTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply